Zobrazeno 1 - 5
of 5
pro vyhledávání: '"A O, Viglinskaia"'
Autor:
D V, Bastrygin, A O, Viglinskaia, G B, Kolyvanov, A A, Litvin, P O, Bochkov, T Ia, Mozhaeva, V P, Zherdev
Publikováno v:
Eksperimental'naia i klinicheskaia farmakologiia. 74(7)
Pharmacokinetics of compound M-11 (main metabolite of afobazole) after administration via different routes was studied in rats. After oral and intravenous administration, M-11 exhibited weakly pronounced bioconversion with the formation of a few meta
Autor:
O V, Shreder, G B, Kolyvanov, A A, Litvin, D V, Bastrygin, E D, Shreder, A S, Solomina, A O, Viglinskaia, V V, Zabrodina, V P, Zherdev, A D, Durnev, S B, Seredenin
Publikováno v:
Eksperimental'naia i klinicheskaia farmakologiia. 73(8)
Afobazole and M-11, its major metabolite were detected in placental and embryonic rat tissues after single peroral administration to pregnant female rats at a dose of 100 mg/kg. The anxiolytic drug and its metabolite are also detected in rat milk and
Autor:
V P, Zherdev, G B, Kolyvanov, A A, Litvin, A K, Sariev, A O, Viglinskaia, B I, Gekkiev, A M, Grigor'ev, V V, Gorlov
Publikováno v:
Eksperimental'naia i klinicheskaia farmakologiia. 73(1)
The pharmacokinetics of dihydroquercetin (DHQ) in the forms of parent substance and a new liposomal formulation (Flamena D) have been studied in rats upon single peroral administration in a dose of 50 mg/kg. DHQ concentration after enzymatic hydrolys
Autor:
S B, Seredenin, A O, Viglinskaia, T Ia, Mozhaeva, G B, Kolyvanov, A A, Litvin, N I, Avdiunina, V L, Savel'ev, V P, Zgerdev
Publikováno v:
Eksperimental'naia i klinicheskaia farmakologiia. 71(2)
Metabolism of afobazole in rats has been studied using mass-spectrometry and HPLC, which revealed 17 products of afobazole biotransformation along with the parent compound. The structures of six afobazole metabolites were established and confirmed by
Publikováno v:
Eksperimental'naia i klinicheskaia farmakologiia. 70(2)
Afobazole pharmacokinetics was studied after the administration via different ways in rats. After oral administration, afobazole is subject to intensive biotransformation with the formation of several metabolites (M-6, M-7, and M-11). The drug and it